MRD negative in the most positive way! DRVD better MRD neg rate than VRD and getting to MRD neg via Dara is likely better.  Congrats to Cesar Rodriguez, MD (Myelomatips.com) and Plasma Cell Pete for keeping the GRIFFIN machine alive! #mmsm #ASCO22

Daratumumab Plus RVd Demonstrates Durable MRD Negativity in Multiple Myeloma onclive.com/view/daratumum… via @onclive Cesar Rodriguez, MD (Myelomatips.com) Mount Sinai Health System #MultipleMyeloma

Dr. ⁦Joshua Richter, MD, FACP⁩ from ⁦⁦The Tisch Cancer Institute⁩ at Mt. Sinai in NYC gives an overview on novel bi-specific antibodies coming to the treatment of myeloma. Happening right now at ⁦Multiple Myeloma RF⁩ patient summit in Miami. #mmsm ⁦Sylvester Comprehensive Cancer Center⁩ ⁦Diko Kazandjian⁩

Become part of our team and make a change in myeloma care. NYSNA ANA — New York Nurse Practitioner Assoc NY State Mount Sinai Health System

Reaching a consensus to define high risk disease is key to develop studies and generate data that could lead to better outcomes in this population. What should this definition include? #IMS2022 #IMS #myeloma Shaji Kumar Ajai Chari Martin Kaiser Joan Bladé Leif Bergsagel @mksamur

Time to wake up the potential of NK-directed therapy in #myeloma. @DrSGandalf showing compelling data to pique our interest. #IMS2022 #IMS

Highly relevant discussion on #CART #bispecifics #CRS & #RRMM therapies JADPRO #JADPROLive Donna Catamero Cesar Rodriguez, MD (Myelomatips.com)

Home for the holidays and taking advantage to connect with the hematologist in #Monterrey Icahn School of Medicine at Mount Sinai The Tisch Cancer Institute #mmsm

Always excited to see how new agents make their way to front line therapy. Will CAR-T and bispecifics jump the line in the coming years????

Junto a hematólogos mexicanos que no dejan de sorprender por cómo se las ingenian para tratar pacientes con mieloma y obtener acceso a inmunoterapias en el ambiente de este país. Excelente evento, y gran respeto #mieloma #hemato #inmunoterapia #luchacontraelcancer #biespecificos

Combinando un poco de cultura con el #IMS23 en Atenas. Combining a bit of culture with the IMS Conference in Athens. International Myeloma Foundation Myeloma Society #myeloma

Another great Immunotherapy in Myeloma preceptorship at The Tisch Cancer Institute, this time with visiting physicians from Argentina. Otro excelente curso en Mount Sinai de Inmunoterapia en Mieloma, esta ocasión nos visitaron médicos de Argentina. #myeloma #mieloma #mmsm #MedTwitter

português, português, portuñol: more things in common than how we spell mieloma

A great meeting with Latin American physicians who are getting ready to roll out CAR-T and bispecific therapies for #myeloma in their countries.

At #ASCO24: Dr. Cesar Rodriguez (Cesar Rodriguez, MD (Myelomatips.com)) presents results for a Phase 1b study exploring dosing schedules for an investigational BCMA directed bispecific antibody in patients with relapsed/refractory #MultipleMyeloma. #mmsm bit.ly/4e7eF70

Come and see what etentamig (formerly known as ABBV-383) combo therapy is doing for #myeloma patients in the bispecifics world. #ASH24 The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai

Can’t agree more with this statement and want to encourage centers in the U.S. to participate in this study. (Contact me for info). #mmsm #ASH24

#HematoTime #ScienceLink Dr. César Rodríguez (Cesar Rodriguez, MD (Myelomatips.com)) buff.ly/JdmCsmO